Hormonal
Phentermine/Topiramate combination therapy significantly reduces the rate of weight regain in patients who have undergone Roux-en-Y gastric bypass (RYGB).
If you are regaining weight after gastric bypass, ask your doctor about Phentermine/Topiramate. It is an oral medication that can help slow down weight regain. It requires a gradual dose increase to minimize side effects like dry mouth or tingling. While not as new as GLP-1 drugs, it has shown promise in keeping weight off in the years following surgery.
A retrospective analysis [129] (n = 760; 350 patients with anti-obesity medication) has shown that the weight regain of patients after RYGB in patients using either phentermine/topiramate (n = 154), topiramate (n = 74), or phentermine (n = 119) has been approximately 10% lower at the end of the 6-year observation period when compared with the control group.
Why this rating
Based on retrospective analysis and one ongoing RCT; no completed RCTs specifically for this drug class post-surgery are cited as completed.
Source
Pharmacotherapy as an Augmentation to Bariatric Surgery for Obesity
L Horvath et al. · Drugs · 2024
DOI 10.1007/s40265-024-02029-0
More from this paper
- Post-bariatric pharmacotherapy with GLP-1 receptor agonists (specifically liraglutide) effectively augments weight loss and prevents weight regain in patients who have undergone Roux-en-Y gastric bypass or sleeve gastrectomy.Good
- Orlistat is effective in promoting weight loss in patients who have undergone Laparoscopic Adjustable Gastric Banding (LAGB) and have plateaued, but its use is not recommended after malabsorptive surgeries.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →